However, a study by Miao et al. showed that PBRM1 deficiency is associated with intermediate (n=17) or significant (n=27) response to anti-PD-L1 therapy in a cohort of 63 ccRCC patients, thereby contradicting with our findings [25]. The gene discussed is CD274; the disease is nonpapillary renal cell carcinoma.